Metabolomics, the study of metabolism at an "omic" level, has the potential to transform our understanding of mechanisms of drug action and the molecular basis for variation in drug response. It is now possible to define metabolic signatures of drug exposure that can identify pathways involved in both drug efficacy and adverse drug reactions. In addition, the "metabotype," the metabolic "signature" of a patient, is a unique identity that contains information about drug response and disease heterogeneity. The application of metabolomics for the study of drug effects and variation in drug response is creating "pharmacometabolomics," a discipline that will contribute to personalized drug therapy and will complement pharmacogenomics by capturing environmental and microbiome-level influences on response to drug therapy. This field has the potential to transform pharmacology and clinical pharmacology in significant ways and will contribute to efforts for personalized therapy.
Your question is very interesting although I'm not aware of publications dealing with the impact of metabolomics in pharmaeconomics, For sure metabolomics is considered one of the possible ways to personalized medicine and as a clinical pharmacologist I fully agree.
As a matter of fact papers on metabolomics increased from 2 in the year 2002 up to 3,889 in 2018 (and the year is not yet at the end) (Ref. PubMed).
In my humble opinion this impact will further increase although is endowed with somewhat greater complexity as there is the need to develop and validate a multitude of biomarkerkers/companion diagnostics to identifiy subsets of patients with specific characteristics so as to recommend targeted treatments.
It is a stream worth pursuing further evem if it's a long way.
I hope this is useful.
Thanks for your valuable input.
Welcome
Metabolomic factor is one out of 5 main factors influencing drug-body interactions and drug response.
The clinical value of metabolomics is that a drug may change hepatic and tissue metabolic activity that may influence physiology or coadminister drugs activity like macrolides and the risk of torade de pointes from metaclopromide. On the other hand metabolomic setup like racial differenxes may influence drug kinetics and response. From overall interactions drug order of kinetics and constants may be altered to be considered therapeutically like Cl, Vd, t1/2 and F
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs